1 fw

PTO/SB/17 (10-03) Approved for use through 7/31/2006. OMB 0651-0032

Under the Paperwork Reduction Act of 1995, no p	ersons are requir	ed to re	spond t				rk Office; U.S. DEPARTMENT OF C on unless it displays a valid OMB cor	
			Complete if Known					
FEE TRANSMITTAL			Application Number			er	10/696,002-Conf. #7776	
10 For EV 200	for FY 2004		Filing Date				October 30, 2003	
(8) S 101 F 2004		r	First N	Vamed	Inver	tor	Jing-Shan Hu	
Effective 10/01/2003. Patent fees are subject to a	nnual revision.	[Exam	iner Na	ame		R. S. Landsman	
Applicant claims small entity status. See	37 CFR 1.27	ľ	Art Un	nit			1647	
APPLICANT Claims small entity status. See	0.00		Attorney Docket No. PF112P3C2US					
METHOD OF PAYMENT (check all tha	t apply)				FEE	CALCU	LATION (continued)	
Courts Disease	ner None	3. A	DDITIC	DNAL				1
X Deposit Account:	— 1	Large	Entity	Small	Entity			
Account 08-3425		Fee Code	Fee (\$)	Fee Code	Fee (\$)		Fee Description	Fee Paid
Deposit Account Human Genome Sciences, In	<u>, </u>	1051	130	2051	65	Surcharge	e – late filing fee or oath	
Name The Director is authorized to: (check all that apply)		1052	50	2052	25	Surcharge sheet.	e - late provisional filing fee or cover	
	overpayments	1053	130	1053	130		sh specification	
X Charge any additional fee(s) or any underpayment of	of fee(s)	1812	2,520	1812	2.520	For filing a	request for ex parte reexamination	
		1804	920*	1804	920*	Requestin	g publication of SIR prior to	
Charge fee(s) indicated below, except for the filing to the above-identified deposit account.	fee		1,840*	1805	1,840*	Examiner Requestin	action g publication of SIR after	
FEE CALCULATION		1251		2251		Examiner	action	
1. BASIC FILING FEE		1251	110 420	2251	55 210		for reply within first month for reply within second month	
Large Entity Small Entity	į	1253	950	2253	475		for reply within third month	
Fee Fee Fee Fee Description	Fee Paid	1254	1,480	2254	740		for reply within fourth month	
Code (\$) Code (\$) 1001 770 2001 385 Utility filing fee		1255	2,010	2255	1,005	Extension	for reply within fifth month	
1002 340 2002 170 Design filing fee		1401	330	2401		Notice of	• •	
1003 530 2003 265 Plant filing fee		1402	330	2402	165	Filing a br	ief in support of an appeal	
1004 770 2004 385 Reissue filing fee		1403	290	2403	145	Request for	or oral hearing	
1005 160 2005 80 Provisional filing fee		1451	1,510	1451	1,510	Petition to	institute a public use proceeding	
SUBTOTAL (1) (\$)	0.00	1452	110	2452	55	Petition to	revive – unavoidable	
SOBIOTAL (I) (\$)	0.00	1453	1,330	2453	665	Petition to	revive - unintentional	
2. EXTRA CLAIM FEES FOR UTILITY ANI	REISSUE	1501	1,330	2501	665	Utility issu	e fee (or reissue)	
Extra Fee from Claims below	Fee Paid	1502	480	2502	240	Design iss	sue fee	
	=	1503	640	2503	320	Plant issue	e fee	
Independent = x	=	1460	130	1460	130	Petitions t	o the Commissioner	
Claims ^	-	1807	50	1807	50	Processin	g fee under 37 CFR 1.17(q)	
Large Entity Small Entity		1806	180	1806	180	Submissio	on of Information Disclosure Stmt	
Fee Fee Fee Fee Code (\$) Fee Descripti	<u>on</u>	8021	40	8021	40		each patent assignment per imes number of properties)	

Independent claims in excess of 3

** Reissue claims in excess of 20

145 Multiple dependent claim, if not paid

** Reissue independent claims

and over original patent

Claims in excess of 20

over original patent

SUBTOTAL (2) (\$)

**or number previously paid, if greater; For Reissues, see above

SUBMITTED BY (Complete (if applicable))						
Name (Print/Туре) Melissa J. Pytel	Registration No. (Altomey/Agent) 41,512	Telephone	(301) 610-5764			
Signature		Date	August 10, 2004			

0.00

Other fee (specify)

*Reduced by Basic Filing Fee Paid

Filing a submission after final rejection (37 CFR 1.129(a))

Request for Continued Examination (RCE)

SUBTOTAL (3) (\$)

0.00

For each additional invention to be examined (37CFR 1.129(b))

Request for expedited examination of a design application



In re Patent Application of: Hu et al. Docket No.: PF112P3C2US

Application No.: 10/696,002 Confirmation No.: 7776

Filed: October 30, 2003 Art Unit: 1647

For: Vascular Endothelial Growth Factor 2 Examiner: Landsman, R.

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of a claim of the subject application, Attorney for Applicants hereby directs the Examiner's attention to references GU and GV listed on the attached Form PTO/SB/08. Copies of the references are enclosed.

Identification of the listed references is not to be construed as an admission of any individual associated with the filing or prosecution of the subject application that such references are available as "prior art" against the subject application. Furthermore, Applicants do not waive any rights to take appropriate action to establish patentability over any of the listed documents should they be applied as references against the claims of the subject application.

The above information is presented so that the Patent and Trademark Office can determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be considered during the prosecution of this application.

Applicants respectfully request that the Examiner review the listed references and that the references be made of record in the file history of the application.

The undersigned certifies pursuant to 37 C.F.R. § 1.97(e)(1) that each item of information contained in this Supplemental Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of this Supplemental Information Disclosure Statement. In particular, the listed references were cited in a European Supplementary Search Report (reference GV) mailed July 14, 2004, in connection with a corresponding international application.

Pursuant to 37 C.F.R. § 1.97(b), this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits. Accordingly, no fee is believed due. However, should the Patent Office determine otherwise, please charge the required fee to our Deposit Account No. 08-3425.

Dated: August 10, 2004

Respectfully submitted,

Melissa J. Pytel

Registration No.: 41,512

HUMAN GENOME SCIENCES, INC.

Intellectual Property Dept. 14200 Shady Grove Road Rockville, Maryland 20850 (301) 610-5764

MMW/MJP/ba



of

1

Sheet

1

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PF112P3C2US

Substitute for form 1449A/B/PTO

Application Number 10/696,002-Conf. #7776

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

10/696,002-Conf. #7776

Filing Date October 30, 2003

First Named Inventor Jing-Shan Hu

Art Unit 1647

Examiner Name R. S. Landsman

Attorney Docket Number

U.S. PATENT DOCUMENTS						
Examiner	Cita	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	
Initials*	Cite No. ¹	Number-Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.1	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

	NON PATENT LITERATURE DOCUMENTS	
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
GU	VALE et al., "Percutaneous Electromechanical Mapping Demonstrates Efficacy of pVGI.1 (VEG2) in an Animal Model of Chronic Myocardial Ischemia," <i>Circulation</i> (Supplement), 100(18):I.22 (Nov. 2, 1999)	
GV	European Supplementary Search Report, Application No. EP 01 96 3814, mailed July 14, 2004	
	No.1	Cite No.1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. GU VALE et al., "Percutaneous Electromechanical Mapping Demonstrates Efficacy of pVGI.1 (VEG2) in an Animal Model of Chronic Myocardial Ischemia," Circulation (Supplement), 100(18):I.22 (Nov. 2, 1999) GV European Supplementary Search Report, Application No. EP 01 96 3814, mailed

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner	Date	
Signature	Considered	

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.